Tag: drug-discovery
-
The Target Identification Problem
Target identification remains the largest source of late-stage clinical failure in drug development. Here's why AI hasn't solved it and what would actually help.
-
Generative Chemistry
Generative AI models are designing drug molecules from scratch. Here's what the chemistry literature reveals about their capabilities, limitations, and failure modes.
-
The FDA and the Machine
The FDA faces the novel challenge of regulating AI-discovered drugs and AI-assisted diagnostics. The institutional response is more sophisticated than critics acknowledge.
-
The Billion-Dollar Bet on Longevity
Longevity biotech has raised billions on AI-accelerated aging science. Here's an honest look at what the biology supports and where the hype has overrun the evidence.
-
The Antibody Engineers
AI-driven antibody engineering is producing therapeutics with properties that natural evolution wouldn't generate. Here's what that capability means for medicine.
-
The Recursion Bet
Recursion Pharmaceuticals built a biological data factory and bet everything on phenomics. Here's what their pipeline reveals about the limits of industrialized discovery.
-
AlphaFold Three Years Later
AlphaFold solved a 50-year problem in structural biology. Here's an honest audit of what that achievement has and hasn't delivered for drug discovery by 2026.
-
Molecules by Machine
AI-designed molecules are entering Phase I and II trials. Here's an honest accounting of which ones, by whom, and what the early data actually shows.
